Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-ALUM50
- Development stage
- Unknown
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CH-ALUM50 is a vaccine adjuvant formulation containing Alhydrogel (aluminum hydroxide) combined with the P27A antigen at a dose of 50 micrograms. It is designed to enhance the immune response to the P27A malaria antigen in clinical studies. The product is administered intramuscularly and has been evaluated for safety and immunogenicity in human volunteers as part of malaria vaccine development efforts[1].
- Brand names
- CH-ALUM50CH-ALUM-50CH-ALUM 50
- Other names
- Alhydrogel CH-Alum50
Beyond the preview
Go deeper on CH-ALUM50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH-ALUM50.